Solid tumor

Blog posts

Cell avidity-tuning ensures safe CAR-T therapy for solid tumors

Dive into our latest article where we shine the spotlight on the groundbreaking work carried out at the Dana-Farber Cancer Institute at Harvard Medical School where researchers utilized cell avidity-tuning to ensure the safety of their CAR-T therapy for targeting solid tumors.

niels5 June 2024

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.